J
Judy Lieberman
Researcher at Boston Children's Hospital
Publications - 299
Citations - 40581
Judy Lieberman is an academic researcher from Boston Children's Hospital. The author has contributed to research in topics: Cytotoxic T cell & Granzyme. The author has an hindex of 93, co-authored 280 publications receiving 34218 citations. Previous affiliations of Judy Lieberman include Harvard University & Children's Medical Center of Dallas.
Papers
More filters
Journal ArticleDOI
let-7 Regulates Self Renewal and Tumorigenicity of Breast Cancer Cells
Fengyan Yu,Fengyan Yu,Herui Yao,Pengcheng Zhu,Xiaoqin Zhang,Qiuhui Pan,Chang Gong,Yijun Huang,Xiaoqu Hu,Fengxi Su,Judy Lieberman,Erwei Song +11 more
TL;DR: Let-7 regulates multiple BT-IC stem cell-like properties by silencing more than one target, and miRNA expression in self-renewing and differentiated cells from breast cancer lines and in breast T-IC and non-BT-IC from 1 degrees breast cancers is compared.
Journal ArticleDOI
Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores
Xing Liu,Zhibin Zhang,Zhibin Zhang,Jianbin Ruan,Jianbin Ruan,Youdong Pan,Venkat Giri Magupalli,Venkat Giri Magupalli,Hao Wu,Hao Wu,Judy Lieberman,Judy Lieberman +11 more
TL;DR: It is shown that GSDMD-NT oligomerizes in membranes to form pores that are visible by electron microscopy and kills cell-free bacteria in vitro and may have a direct bactericidal effect within the cytosol of host cells, but the importance of direct bacterial killing in controlling in vivo infection remains to be determined.
Journal ArticleDOI
Identification of Host Proteins Required for HIV Infection Through a Functional Genomic Screen
Abraham L. Brass,Derek M. Dykxhoorn,Yair Benita,Nan Yan,Alan Engelman,Ramnik J. Xavier,Judy Lieberman,Stephen J. Elledge +7 more
TL;DR: This article performed a large-scale small interfering RNA screen to identify host factors required by HIV-1 and identified more than 250 HIV-dependency factors (HDFs), which participate in a broad array of cellular functions and implicate new pathways in the viral life cycle.
Journal ArticleDOI
Interfering with disease: a progress report on siRNA-based therapeutics.
TL;DR: The considerations that go into developing RNAi-based therapeutics starting from in vitro lead design and identification, to in vivo pre-clinical drug delivery and testing are discussed and the latest clinical experience with RNAi therapeutics is reviewed.
Journal ArticleDOI
RNA interference targeting Fas protects mice from fulminant hepatitis
Erwei Song,Sang-Kyung Lee,Jie Wang,Nedim Ince,Nengtai Ouyang,Jun Min,Jisheng Chen,Premlata Shankar,Judy Lieberman +8 more
TL;DR: In a more fulminant hepatitis induced by injecting agonistic Fas-specific antibody, 82% of mice treated with siRNA that effectively silenced Fas survived for 10 days of observation, whereas all control mice died within 3 days.